trastuzumab deruxtecan + volrustomig + carboplatin

A combination regimen of **trastuzumab deruxtecan**, **volrustomig**, and **carboplatin**, investigated primarily for cancer therapy in settings such as HER2-positive and other advanced solid tumors. - **Trastuzumab deruxtecan** is an antibody-drug conjugate combining a humanized anti-HER2 monoclonal antibody (trastuzumab) with a topoisomerase I inhibitor payload, designed to selectively deliver cytotoxic therapy to HER2-expressing tumor cells. - **Volrustomig** is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4, functioning as a dual immune checkpoint inhibitor to enhance antitumor immune responses. - **Carboplatin** is a small molecule, platinum-based alkylating agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. This combination is administered intravenously and is being evaluated for anti-tumor activity and safety in various solid tumor malignancies, with recent development specifically noted in early-phase clinical studies.

Other names

EnhertuDS-8201DS8201DS 8201DS-8201aDS8201aDS 8201aMEDI5752MEDI-5752MEDI 5752volrustomigCBDCAcis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)Paraplatin